Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs

Journal of Infection

Volumn 44, Issue 3, 2002, Pages 160-165

  Tomioka, H ^a   Sato, K ^a   Shimizu, T ^a   Sano, C ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFALAZIL; RIFAMPICIN; SITAFLOXACIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CELL DIVISION; CLINICAL STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; MACROPHAGE; MEDICAL ASSESSMENT; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OBSERVATION; TUBERCULOSIS;

EID: 0036556506     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2002.0973     Document Type: Article

References (32)

1. Ellner JJ, Goldberger MJ, Parenti DM. Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. J Infect Dis 1991; 163: 1326-1335.
2. Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996: 9: 177-215.
3. Hart CA, Beeching NJ, Duerden BI. Tuberculosis into the next century. J Med Microbiol 1996; 44: 1-34.
4. Cohn DL, Iseman MD. Treatment and prevention of multidrug-resistant tuberculosis. Res Microbiol 1993: 144: 150-153.
5. Leysen DC, Haemers A, Pattyn SR. Mycobacteria and the new quinolones. Antimicrob Agents Chemother 1989; 33: 1-5.
6. Alangaden GJ. Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997; 25: 1213-1221.
7. Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicicities in humans. Antimicrob Agents Chemother 1985; 28: 716-1721.
8. Ji B, N Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995: 39: 1341-1344.
9. Klemens SP, Sharpe CA, Rogge MC, Cynamon MH. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother 1994; 38: 1470-1479.
10. Tomioka H. Prospects for development of new antimycobacterial drugs. J Infect Chemother 2000; 6: 8-20.
11. Rastogi N, Goh KE, Bryskier A. Devallois A. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 1610-1616.
12. Sbarbaro JA. Iseman MD, Crowle A. Combined effect of pyrazinamide and ofloxacin within human macrophage. Tuberc Lung Dis 1996; 77: 491-495.
13. Tomioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother 1993; 37: 1259-1263.
14. Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999; 43: 3001-3004.
15. Saito H, Tomioka H, Sato K, Dekio S. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrob Agents Chemother 1994: 38: 2877-2882.
16. Dong Y, Xu C, Zhao X, Domagala J, DrIica K. Fluoroquinolone action against Mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother 1998; 42: 2978-2984.
17. Zhao BY, Pine R, Domagala J, DrIica K. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxy group on survival in liquid media and human macrophages. Antimicrob Agents Chemother 1999; 43: 661-666.
18. Saito H, Sato K, Tomioka H, Dekio S. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tuberc Lung Dis 1995; 76: 377-380.
19. Hirata T, Saito H, Tomioka H, Sato K, Jidoi J, Hosoe K, Hidaka T. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995: 39: 2295-2303.
20. Doi N. Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis. Kekkaku 1998; 73: 53-64.
21. Doi N. Development of the intratracheal infection model of experimental marine tuberculosis: Comparison with the intravenous infection model. Kekkaku 1998: 73: 339-347.
22. Yamada H, Mizuno S, Reza-Ghlizadeh M, Sugawara I. Relative importance of NF-κB p50 in mycobacterial infection. Infect Immun 2001; 69: 7100-7105.
23. Yajko DM, Nassos PS, Hadley WK. Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome. Antimicrob Agents Chemother 1987: 31: 1579-1584.
24. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 2066-2069.
25. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE. Bishai WR. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999: 43: 85-89.
26. Rastogi N, Labrousse V, Bryskier A. Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother 1995; 39: 976-978.
27. Bermudez LE, Inderlied CB, Kolonoski P, Wu M, Barbara-Burnham L, Young LS. Acitivities of Bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. Antimicrob Agents Chemother 1996: 40: 546-551.
28. Pellegrin I, Maugein J, Lapeyre C, Barbeau P, Leng B, Pellegrin J-L. Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages. Int J Antimicrob Agents 1996; 37: 501-510.
29. Tomioka H, Sano C, Sato K, Shimizu T. Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex. Int J Antimicrob Agents 2002 (in press).
30. Dannenberg AM Jr, Rook AW. Pathogenesis of pulmonary tuberculosis: an interplay of tissue-damaging and macrophage activating immune responses-Dual mechanisms that control bacillary multiplication. In: Bloom BR (ed.) Tuberculosis: Pathogenesis, Protection, and Control. ASM Press, 1994: 459-483.
31. Crowle AJ, Dahl R, Ross E, May MH. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect Immun 1991; 59: 1823-1831.
32. Pieters J. Evasion of host cell defense mechanisms by pathogen bacteria. Curr Opin Immunol 2001; 13: 37-44.